Back to results
US 2020/0046731 A1Published application
Bioavailable solid state (17- β)-hydroxy-4-androsten-3-one esters
AssigneeLipocine Inc.
InventorsMahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
Life of this patent
Estimating the term…
Abstract
Disclosed are bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-β)-Hydroxy-4-Androsten-3-one.
Claims20
A solid state (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate suitable for administration to human subject in need of (17-β)-Hydroxy-4-Androsten-3-one.
A pharmaceutical composition, comprising or prepared from a solid state pharmaceutical ingredient comprising a solid state (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.